Diabetic Kidney Disease Global Market Research Report 2024
March 25, 2024 11:05 ET
|
Research and Markets
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The diabetic kidney disease market size...
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
March 18, 2024 07:57 ET
|
ZyVersa Therapeutics
Initiation of Phase 2a trial first half 2024 with Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease is a key milestone for ZyVersa.
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
January 03, 2024 16:13 ET
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
December 14, 2023 07:01 ET
|
ZyVersa Therapeutics
ZyVersa engages CRO, George Clinical, to manage its P2a clinical trial with VAR 200 in Diabetic Kidney Disease expected to begin Q1-2024.
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
December 07, 2023 11:20 ET
|
ZyVersa Therapeutics
Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.
Global Sales of Diabetic Nephropathy Market is Expected to Accelerate at a Whopping 6.70% CAGR, Reaching US$ 4.86 Billion by 2033: Persistence Market Research
October 19, 2023 10:44 ET
|
Persistence Market Research
New York, Oct. 19, 2023 (GLOBE NEWSWIRE) -- In 2022, global revenue for Diabetic Nephropathy reached approximately $2.37 billion, projected to grow at a 6.70% CAGR, hitting $4.86 billion by 2033. It...
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
June 06, 2023 09:07 ET
|
ZyVersa Therapeutics
Cholesterol Transport Mediator™ VAR 200 is in development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular diseases, including...
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
May 15, 2023 09:07 ET
|
ZyVersa Therapeutics
Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
March 01, 2023 09:20 ET
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...
Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
August 16, 2015 20:28 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...